Contact Us

AUA Advocacy Communications

10 G Street NE
Suite 600
Washington, D.C. 20002

1-866-RING-AUA (toll-free)
410-689-3810 (direct)

Home Press Center Press Releases  Press Release

Press Releases

Urologists Explore the Role of Robotics, Equity, Exercise and Medicine on Bladder Cancer

NEW ORLEANS, May 14, 2022 /PRNewswire/ -- Do socioeconomic disparities impact a bladder cancer patient's care?  Can exercise improve the health of bladder cancer patients during treatment? What technologic and pharmacologic advances are urologists utilizing to treat bladder cancer?

Researchers will be presenting these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA). Benjamin Davies, MD, professor of urology at the University of Pittsburgh School of Medicine and director of the Urologic Oncology Program at the Shadyside/Hillman Cancer Center, will moderate a press session featuring the following four abstracts at the Ernest N. Morial Convention Center in New Orleans on May 14, 2022, at 11 a.m. CT.

Boris Gershman, MD, at Beth Israel Deaconess Medical Center, investigated socioeconomic disparities and their potential impact on the management of non-muscle-invasive bladder cancer (NMIBC) despite strong clinical practice guidelines. "Disparities in the Prevalence and Management of High-Risk Non-Muscle Invasive Bladder Cancer"

Not much is known about the impact of a patient's behavioral habits on bladder cancer, so Mara Koelker, MD, at Brigham and Women's Hospital, investigated the role of exercise on self-reported physical health status. "Impact of Exercise on Physical Health Status in Bladder Cancer Patients"

Pramit Khetrapal, MD, at University College London, explored the utilization of intracorporeal robot-assisted RC (iRARC) vs open RC (ORC) and the impact on a bladder cancer patient's recovery time. "Results of the Intracorporeal Robotic vs Open Cystectomy (iROC) Multi-Centre Randomised Trial"

Disease-free survival was significantly improved with adjuvant nivolumab vs. placebo in patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after radical surgery, according to Icahn School of Medicine at Mount Sinai's Matthew Galsky, MD. "Disease-Free Survival With Longer Follow-Up From the CheckMate 274 Trial of Adjuvant Nivolumab in Patients After Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma"

"The bladder cancer session highlights technologic and pharmacologic advances in bladder cancer care as well as important work on equity and exercise," said Dr. Davies.

About the American Urological Association:  The 117th Annual Meeting of the American Urological Association takes place May 13-16 at the Ernest N. Morial Convention Center in New Orleans. Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology and has nearly 24,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.

Media Contact:
Caitlin Lukacs, Corporate Communications and Media Relations Manager

SOURCE American Urological Association

For further information: NOTE TO REPORTERS: Presenting authors and moderators are available to discuss their findings outside normal briefing times. To arrange an interview with an expert, please contact the AUA Communications team at